Location History:
- Newton, MA (US) (2005)
- Auburndale, MA (US) (2004 - 2012)
Company Filing History:
Years Active: 2004-2012
Title: Kevin Delos Parris: Innovator in Antibody Research
Introduction
Kevin Delos Parris is a notable inventor based in Auburndale, MA (US). He has made significant contributions to the field of immunology, particularly through his work on antibodies targeting human interleukin-13. With a total of seven patents to his name, Parris has established himself as a key figure in the development of therapeutic solutions for various IL-13-associated disorders.
Latest Patents
Among his latest patents, Parris has developed antibodies against human interleukin-13 and their pharmaceutical compositions. These applications focus on humanized antibodies and antigen-binding fragments that specifically bind to interleukin-13 (IL-13). The antibodies are designed to regulate immune responses mediated by IL-13, making them useful in diagnosing, preventing, and treating a range of disorders. These include respiratory conditions such as asthma, atopic disorders like allergic rhinitis, and inflammatory or autoimmune conditions affecting the skin and gastrointestinal organs. Additionally, they hold potential in addressing fibrotic and cancerous disorders.
Career Highlights
Throughout his career, Parris has worked with prominent companies, including Wyeth. His experience in the pharmaceutical industry has allowed him to contribute to groundbreaking research and development in antibody therapies. His innovative work has paved the way for advancements in treating complex medical conditions.
Collaborations
Parris has collaborated with notable colleagues, including Laura Lin and Mark L Stahl. These partnerships have further enhanced his research efforts and contributed to the success of his projects.
Conclusion
Kevin Delos Parris is a distinguished inventor whose work in antibody research has the potential to transform the treatment of various IL-13-associated disorders. His innovative patents and collaborations highlight his commitment to advancing medical science.